Vasoactive intestinal peptide in pulmonary arterial hypertension: Reply

American Journal of Respiratory and Critical Care Medicine

Volumn 185, Issue 7, 2012, Pages 786-

  Galie, Nazzareno ^a   Palazzini, Massimiliano ^a   Manes, Alessandra ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

VASOACTIVE INTESTINAL POLYPEPTIDE;

DRUG SAFETY; HUMAN; LETTER; LUNG HEMODYNAMICS; MEDICAL LITERATURE; MEDICAL RESEARCH; PRIORITY JOURNAL; PULMONARY HYPERTENSION; TREATMENT OUTCOME;

EID: 84859480318     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/ajrccm.185.7.786a     Document Type: Letter

References (4)

1. Bodanszky M, Klausner YS, Lin CY, Mutt V, Said SI. Synthesis of the vasoactive intestinal peptide (VIP). J Am Chem Soc 1974;96:4973-4978.
2. Galie N, Boonstra A, Ewert R, Gomez-Sanchez MA, Barbera JA, Torbicki A, Bremer H, Ghofrani A, Naeije R, Gruenig E, et al. Effects of inhaled Aviptadil (vasoactive intestinal peptide) in patients with pulmonary arterial hypertension (PAH) [abstract]. Am J Respir Crit CareMed 2010;181:A2516.
3. Petkov V, Mosgoeller W, Ziesche R, Raderer M, Stiebellehner L, Vonbank K, Funk GC, Hamilton G, Novotny C, Burian B, et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 2003;111:1339-1346. (Pubitemid 36554704)
4. Leuchte HH, Baezner C, Baumgartner RA, Bevec D, Bacher G, Neurohr C, Behr J. Inhalation of vasoactive intestinal peptide in pulmonary hypertension. Eur Respir J 2008;32:1289-1294.